A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by Astellas Pharma Inc.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Astellas Pharma Korea, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT01505439
First received: January 4, 2012
Last updated: NA
Last verified: January 2012
History: No changes posted

January 4, 2012
January 4, 2012
June 2011
April 2012   (final data collection date for primary outcome measure)
Changes in the number of urge urinary incontinence episodes per 24 hours between baseline and week 12 [ Time Frame: Baseline and week 12 ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
  • Percent change in the mean number of urge urinary incontinence episodes per 24 hours [ Time Frame: Baseline, week 4 and week 12 ] [ Designated as safety issue: No ]
  • Change in the mean number of urge urinary incontinence episodes per 24 hours [ Time Frame: Baseline, week 4 and week 12 ] [ Designated as safety issue: No ]
    urgency episodes: defined as those with a Bladder Sensation Scale rating of ≥ 3 in the voiding diary
  • Change in the mean frequency of urination per 24 hours [ Time Frame: Baseline, week 4 and week 12 ] [ Designated as safety issue: No ]
  • Percent change in the mean frequency of urination [ Time Frame: Baseline, week 4 and week 12 ] [ Designated as safety issue: No ]
  • Changes in the mean and sum rating on the Bladder Sensation Scale per 24 hours [ Time Frame: Baseline, week 4 and week 12 ] [ Designated as safety issue: No ]
  • Change in the mean number of severe urgency episodes per 24 hours [ Time Frame: Baseline, week 4 and week 12 ] [ Designated as safety issue: No ]
    severe urgency episodes: defined as those with a Bladder Sensation Scale rating of ≥ 4 in the voiding diary
  • Changes in overactive bladder symptom score (OABSS) questionnaire [ Time Frame: Baseline, week 4 and week 12 ] [ Designated as safety issue: No ]
    Change in total and each of OABSS items
  • Changes in short urogenital distress inventory (UDI-6) [ Time Frame: Baseline, week 4 and week 12 ] [ Designated as safety issue: No ]
    Change in total and each UDI-6 items
  • Changes in short incontinence impact questionnaire (IIQ-7) [ Time Frame: Baseline, week 4 and week 12 ] [ Designated as safety issue: No ]
    Change in total and each of IIQ-7 items
  • Safety assessed by the incidence and severity of side effects [ Time Frame: For 12 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence
A Prospective, Open Label, Single Arm, Multicenter Study to Estimate the Efficacy and Safety of Solifenacin in Female With Clinically Significant Stress Urinary Incontinence and Urgency Urinary Incontinence

This study is to investigate the effects of solifenacin on urgency urinary incontinence symptoms and incontinence quality-of-life (I-QoL) in female patients with clinically significant stress urinary incontinence accompanied by urgency urinary incontinence.

Not Provided
Interventional
Phase 4
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Stress Urinary Incontinence
  • Urgency Urinary Incontinence
Drug: solifenacin
oral
Other Name: Vesicare
Experimental: Solifenacin group
Intervention: Drug: solifenacin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
April 2012
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients are selected from those who meets one of criteria
  • Patients with a positive cough provocation test
  • Based on 3-day voiding diary, patients with:

    • Urinary frequency (eight or more micturitions per day or 24 hours)
    • Urinary urgency (two or more episodes per day or 24 hours)
    • Urge incontinence (three or more episodes for 3 days)

Exclusion Criteria:

  • Breast-feeding women or females of childbearing potential with the intention to become pregnant during the study
  • Post-void residual urine volume (PRV) of 150 cc or more
  • Patients who experienced acute ureteral obstruction requiring an indwelling catheter
  • Patients who experienced clinically significant pelvic organ prolapse or lower urinary tract surgery within 6 months prior to the initiation of the present study
  • Patients who underwent a urinary incontinence operation within 1 year
  • Any condition that, in the opinion of the investigator, is a contraindication for anticholinergic treatment, including severe narrow-angled glaucoma, urinary retention, gastric retention, severe myasthenia, severe hepatic insufficiency or severe ulcerative colitis
  • Significant hepatic or renal disease, defined as having greater than twice the upper limit of the reference ranges for serum concentrations of aspartate aminotransferase (AST [SGOT]), alanine aminotransferase (ALT [SGPT]), alkaline phosphatase or creatinine
  • Patients who have any of neurological disorders such as stroke, multiple sclerosis, spinal cord injury, and Parkinson's disease
  • Patients who use an indwelling catheter or practice intermittent self-catheterization
  • Recurrent UTIs defined as having been treated for symptomatic UTIs 3 times or more in the last year
  • Symptomatic acute urinary tract infection (UTI) during the run-in period
  • Patients who received any of the following prohibited concomitant drugs within 14 days prior to randomization: Treatment performed within the 14 days preceding randomization, or expected to initiate treatment during the study with:

    • Any anticholinergics other than the trial drug
    • Any drug treatment for overactive bladder. Estrogen treatment started more than 2 months prior to inclusion is allowed
  • Patients taking an unstable dosage of any drug with anticholinergic side effects, or expected to start such treatment during the study
  • Patients with chronic constipation or history of severe constipation
  • Treatment with any of potent CYP3A4 inhibitors, such as cyclosporine, vinblastine, macrolide antibiotics (e.g. erythromycin, clarithromycin, azithromycin) or antifungal agents (e.g. ketoconazole, itraconazole, micronazole)
  • Sexually active females of childbearing potential not using reliable contraception for at least 1 month prior to study initiation and not agreeing to use such methods during the entire study period and for at least 1 month thereafter. Reliable contraceptive methods are defined as intrauterine devices (IUDs), combination type contraceptive pills, hormonal implants, double barrier method, injectable contraceptives, surgical procedures (tubal ligation or vasectomy), or continence
  • Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion
Female
18 Years and older
No
Contact: Clinical Development Administration Dept. clinicaltrials_info@jp.astellas.com
Korea, Republic of
 
NCT01505439
VENUS-MUI
No
Astellas Pharma Inc
Astellas Pharma Inc
Astellas Pharma Korea, Inc.
Study Chair: Use Central Contact Astellas Pharma Inc
Astellas Pharma Inc
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP